Castillo Viviana, Valenzuela Rodrigo, Huidobro Christian, Contreras Hector R, Castellon Enrique A
Laboratory of Molecular and Cellular Andrology, Physiology and Biophysics Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
Urology Service, Clinical Hospital, University of Chile, Santiago 8380453, Chile.
Int J Oncol. 2014 Sep;45(3):985-94. doi: 10.3892/ijo.2014.2529. Epub 2014 Jun 27.
Cancer stem cells (CSCs) have the ability to self-renew and differentiate to give rise to heterogeneous phenotype of the tumor cells. It is believed that these cells are involved in metastasis, recurrence and therapy resistance in various cancers. CSCs have been identified in prostate cancer (PCa), one of the most diagnosed malignancies in men over the world, for which chemotherapy resistance is a major problem in the treatment of castration-resistant advanced stages. Molecular signatures, gene expression and functional features have been reported for PCa CSCs. Most data come from cell lines which may not represent the actual tumor. In the present work, a CSCs enriched population obtained from PCa explants was functionally characterized and analyzed for drug resistance. Tumorsphere cultures positive for ABCG2 transporter, CD133, CD44, cytokeratins 5 and 18 (CK5 and CK18) and negatives for androgen receptor (AR) and prostate-specific antigen (PSA) showed higher clonogenic capacity, holoclone-forming ability, colony-forming capacity in soft agar and lower proliferative and apoptotic rate than control adherent cell cultures. Furthermore, exposing tumorsphere cultures to ABCG2 substrate drugs resulted in a high survival rate compared with control PCa cells. This high drug resistance was decreased using a selective inhibitor of ABCG2. According to these results, tumorspheres from PCa explants showed a functional stem phenotype and a marked drug resistance, probably mediated by high expression of the ABCG2 transporter, which might be considered as a suitable therapeutic target for CSCs.
癌症干细胞(CSCs)具有自我更新和分化的能力,能够产生肿瘤细胞的异质性表型。据信,这些细胞参与了多种癌症的转移、复发和治疗抵抗。在前列腺癌(PCa)中已鉴定出癌症干细胞,PCa是全球男性中最常被诊断出的恶性肿瘤之一,对于去势抵抗性晚期PCa的治疗而言,化疗抵抗是一个主要问题。已有关于PCa癌症干细胞的分子特征、基因表达和功能特性的报道。大多数数据来自细胞系,而细胞系可能无法代表实际的肿瘤。在本研究中,对从PCa外植体获得的富集癌症干细胞群体进行了功能表征和耐药性分析。对ABCG2转运蛋白、CD133、CD44、细胞角蛋白5和18(CK5和CK18)呈阳性,而对雄激素受体(AR)和前列腺特异性抗原(PSA)呈阴性的肿瘤球培养物,与对照贴壁细胞培养物相比,显示出更高的克隆形成能力、全克隆形成能力、软琼脂中的集落形成能力以及更低的增殖和凋亡率。此外,与对照PCa细胞相比,将肿瘤球培养物暴露于ABCG2底物药物中可导致较高的存活率。使用ABCG2的选择性抑制剂可降低这种高耐药性。根据这些结果,来自PCa外植体的肿瘤球表现出功能性干细胞表型和显著的耐药性,这可能是由ABCG2转运蛋白的高表达介导的,ABCG2转运蛋白可能被视为癌症干细胞的一个合适治疗靶点。